CTLA4 and neoplasm: However, through the application of antibodies that block negative feedback mechanisms—such as anti‐PD‐1, anti‐PD‐L1 and anti‐CTLA4—it's possible to induce tumour antigen‐specific immune responses and ultimately, eradicate the tumours.27